| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
LHRH targets the gonadotropin-releasing hormone receptor (GnRHR), a G-protein coupled receptor expressed on pituitary gonadotrophs. By binding to this receptor, LHRH stimulates the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary, which in turn regulates gonadal function.
|
|---|---|
| ln Vitro |
In vitro, LHRH binds to the GnRH receptor with high affinity and stimulates LH and FSH release from cultured pituitary cells in a concentration-dependent manner. The peptide activates downstream signaling pathways through G-protein coupling, leading to the synthesis and secretion of gonadotropins.
|
| ln Vivo |
In vivo, LHRH regulates the reproductive axis by stimulating the release of LH and FSH from the pituitary. It is used in research to study the hypothalamic-pituitary-gonadal (HPG) axis and reproductive endocrinology. The peptide is also used in diagnostic testing of pituitary function.
|
| Enzyme Assay |
Receptor binding assays for LHRH use membrane preparations from cells expressing the GnRH receptor. Radiolabeled LHRH or a related analog is incubated with varying concentrations of the test compound, and binding affinity is determined by competition binding curves.
|
| Cell Assay |
Cellular assays for LHRH utilize primary pituitary cell cultures or immortalized gonadotrope cell lines. Cells are treated with the peptide, and LH and FSH secretion into the culture medium is measured by radioimmunoassay or ELISA. Intracellular signaling can also be assessed.
|
| Animal Protocol |
In vivo studies with LHRH are conducted in rodent or primate models. The peptide is typically administered via intravenous, subcutaneous, or intraperitoneal injection. Serum LH and FSH levels are measured at various time points to assess pituitary responsiveness.
|
| ADME/Pharmacokinetics |
As a peptide, LHRH has a short half-life in circulation due to rapid proteolytic degradation. The free acid form (CAS 35263-73-1) is a related compound to the native LHRH amide. The compound should be stored under appropriate conditions to maintain stability.
|
| Toxicity/Toxicokinetics |
Toxicity data for LHRH are limited. Peptide hormones are generally well-tolerated at physiological concentrations. Standard safety precautions for laboratory handling of peptides should be followed.
|
| References | |
| Additional Infomation |
LHRH (free acid) is a research-use peptide and is not approved for therapeutic applications. It is also known as 10-Glycine-LHRH and is a sequence variant impurity resulting from glycine incorporation at residue 10 of the LHRH peptide backbone. It is used in reproductive endocrinology research.
|
| Molecular Formula |
C55H74N16O14
|
|---|---|
| Molecular Weight |
1183.27486
|
| Exact Mass |
1182.56
|
| CAS # |
35263-73-1
|
| PubChem CID |
3081473
|
| Appearance |
White to off-white solid powder
|
| Density |
1.54 g/cm3
|
| Index of Refraction |
1.709
|
| LogP |
1.006
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
31
|
| Heavy Atom Count |
85
|
| Complexity |
2390
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
|
| InChi Key |
IGACZQNUZMBGFX-AQJXLSMYSA-N
|
| InChi Code |
InChI=1S/C55H74N16O14/c1-29(2)19-38(49(80)66-37(9-5-17-59-55(56)57)54(85)71-18-6-10-43(71)53(84)62-26-46(76)77)65-45(75)25-61-47(78)39(20-30-11-13-33(73)14-12-30)67-52(83)42(27-72)70-50(81)40(21-31-23-60-35-8-4-3-7-34(31)35)68-51(82)41(22-32-24-58-28-63-32)69-48(79)36-15-16-44(74)64-36/h3-4,7-8,11-14,23-24,28-29,36-43,60,72-73H,5-6,9-10,15-22,25-27H2,1-2H3,(H,58,63)(H,61,78)(H,62,84)(H,64,74)(H,65,75)(H,66,80)(H,67,83)(H,68,82)(H,69,79)(H,70,81)(H,76,77)(H4,56,57,59)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1
|
| Chemical Name |
2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8451 mL | 4.2255 mL | 8.4511 mL | |
| 5 mM | 0.1690 mL | 0.8451 mL | 1.6902 mL | |
| 10 mM | 0.0845 mL | 0.4226 mL | 0.8451 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
